See more : QS Energy, Inc. (QSEP) Income Statement Analysis – Financial Results
Complete financial analysis of Aadi Bioscience, Inc. (AADI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aadi Bioscience, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Parfex SA (MLPFX.PA) Income Statement Analysis – Financial Results
- The Goodyear Tire & Rubber Company (GT.SW) Income Statement Analysis – Financial Results
- Platzer Fastigheter Holding AB (publ) (PLAZ-B.ST) Income Statement Analysis – Financial Results
- TQM Alpha Public Company Limited (TQM-R.BK) Income Statement Analysis – Financial Results
- Arctic Minerals AB (publ) (ARCT.ST) Income Statement Analysis – Financial Results
Aadi Bioscience, Inc. (AADI)
About Aadi Bioscience, Inc.
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 24.35M | 15.22M | 1.00M | 14.00M | 749.00K | 20.16M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.81M | 1.34M | 276.00K | 176.00K | 76.50K | 0.00 | 51.27K | 69.67K | 57.98K | 23.97K | 22.82K | 22.39K | 23.59K | 20.51K | 0.00 | 0.00 |
| Gross Profit | 21.55M | 13.88M | 724.00K | 13.82M | 672.50K | 20.16M | -51.27K | -69.67K | -57.98K | -23.97K | -22.82K | -22.39K | -23.59K | -20.51K | 0.00 | 0.00 |
| Gross Profit Ratio | 88.47% | 91.23% | 72.40% | 98.74% | 89.79% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 48.93M | 32.66M | 19.67M | 15.01M | 12.82M | 17.85M | 12.15M | 11.37M | 11.63M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 18.51M | 2.12M | 1.85M | 13.49M | 9.24M | 29.49K | 23.01K | 22.82K | 22.39K | 23.59K | 20.51K | 20.51K | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 7.83M | -46.69K | -51.27K | 5.17M | 5.78M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 44.55M | 40.18M | 18.51M | 2.12M | 9.68M | 13.44M | 9.19M | 5.20M | 5.80M | 22.82K | 22.39K | 23.59K | 20.51K | 20.51K | 0.00 | 0.00 |
| Other Expenses | 0.00 | 5.06M | -120.00K | -580.00K | -142.73K | -6.39K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -33.62K |
| Operating Expenses | 93.48M | 72.84M | 38.06M | 16.55M | 22.50M | 31.29M | 21.34M | 16.56M | 17.43M | 22.82K | 22.39K | 23.59K | 20.51K | 20.51K | 0.00 | -33.62K |
| Cost & Expenses | 96.29M | 74.17M | 38.06M | 16.55M | 22.58M | 31.34M | 21.39M | 16.63M | 17.49M | 22.82K | 22.39K | 23.59K | 20.51K | 41.02K | 0.00 | -33.62K |
| Interest Income | 6.40M | 2.40M | 13.00K | 41.00K | 1.03M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 231.00K | 230.00K | 665.00K | 815.00K | 0.00 | 778.22K | -105.78K | 9.94K | 8.43K | 5.88K | 4.97K | 3.60K | 1.89K | 1.89K | 0.00 | 0.00 |
| Depreciation & Amortization | 169.00K | 159.00K | 276.00K | 176.00K | 76.50K | 46.69K | 51.27K | 69.67K | 57.98K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -65.37M | -60.12M | -109.15M | -2.49M | -24.44M | -10.35M | -21.24M | -16.43M | -17.01M | -22.82K | -22.39K | -23.59K | -20.51K | -41.02K | 0.00 | -33.62K |
| EBITDA Ratio | -268.40% | -371.71% | -3,546.30% | -18.94% | -3,004.55% | -55.24% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -71.93M | -58.96M | -111.22M | -2.55M | -22.58M | -11.18M | -21.39M | -16.63M | -17.49M | -22.82K | -22.39K | -23.59K | -20.51K | -41.02K | 0.00 | -33.62K |
| Operating Income Ratio | -295.36% | -387.47% | -11,121.70% | -18.21% | -3,014.77% | -55.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 6.17M | 2.17M | 1.13M | -927.00K | 1.17M | 784.61K | -12.07K | -349.93K | 416.33K | 17.15K | 16.95K | 17.42K | 19.99K | 18.62K | 0.00 | 0.00 |
| Income Before Tax | -65.77M | -60.51M | -110.09M | -3.48M | -23.27M | -10.40M | -21.40M | -16.98M | -17.07M | -28.70K | -27.37K | -27.19K | -22.40K | -22.40K | 0.00 | -33.62K |
| Income Before Tax Ratio | -270.04% | -397.69% | -11,008.80% | -24.83% | -3,106.88% | -51.58% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -3.50M | 2.00K | 2.00K | 1.30K | 778.22K | -12.06K | -3.00 | 3.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -65.77M | -57.01M | -110.09M | -3.48M | -23.27M | -10.40M | -21.40M | -16.98M | -17.07M | -28.70K | -27.37K | -27.19K | -22.40K | -22.40K | 0.00 | -33.62K |
| Net Income Ratio | -270.04% | -374.67% | -11,009.00% | -24.84% | -3,106.88% | -51.58% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.44 | -2.53 | -12.34 | -20.52 | -8.60 | -4.60 | -14.81 | -9.42 | -9.47 | -0.02 | -0.02 | -0.02 | -0.01 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -2.44 | -2.53 | -12.34 | -20.52 | -8.60 | -4.60 | -14.81 | -9.42 | -9.47 | -0.02 | -0.02 | -0.02 | -0.01 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 26.92M | 22.51M | 8.92M | 169.49K | 2.71M | 2.26M | 1.44M | 1.80M | 1.80M | 1.80M | 1.80M | 1.80M | 1.80M | 5.00M | 0.00 | 0.00 |
| Weighted Avg Shares Out (Dil) | 26.92M | 22.51M | 8.92M | 169.49K | 2.71M | 2.26M | 1.44M | 1.80M | 1.80M | 1.80M | 1.80M | 1.80M | 1.80M | 5.00M | 0.00 | 0.00 |
Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting
nab-Sirolimus demonstrated significantly greater intratumoral drug concentration, stronger inhibition of mTOR targets and greater antitumor activity compared to IV and oral mTOR inhibitors in a xenograft model Data support further clinical exploration of nab-sirolimus as a single agent or in...
Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update
Fully enrolled registration-intended PRECISION1 trial; two-thirds interim analysis planned for Q3 2024 FYARRO® sales of $5.4 million for Q1 2024, reflects distributor ordering patterns and fewer commercial patient initiations at the start of the year Conference call to be held...
Aadi Bioscience to Report First Quarter 2024 Results and Corporate Update
Company to Host Conference Call and Webcast on May 8, 2024 LOS ANGELES , May 1, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the...
Aadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual Meeting
Data further support clinical exploration of nab-sirolimus in combination with endocrine therapy for hormone-driven cancers, as is currently being investigated for patients with endometrioid-type endometrial cancer in a Phase 2 trial Data highlight potential for synergy to enhance anti-cancer effects...
Is Aadi Bioscience (AADI) Stock Outpacing Its Medical Peers This Year?
Here is how Aadi Bioscience, Inc. (AADI) and Amplifon S.p.A. (AMFPF) have performed compared to their sector so far this year.
Is Aadi Bioscience (AADI) Outperforming Other Medical Stocks This Year?
Here is how Aadi Bioscience, Inc. (AADI) and Amplifon S.p.A. (AMFPF) have performed compared to their sector so far this year.
Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO)
Subgroup experienced efficacy and safety consistent with overall study population Advanced malignant PEComa tumors of gynecologic origin accounted for more than half of the evaluable patients enrolled in AMPECT Additional data presented highlight nab-sirolimus as potential approach for mTOR-driven gynecologic...
Aadi Bioscience, Inc. (AADI) Q4 2023 Earnings Call Transcript
Aadi Bioscience, Inc. (AADI) Q4 2023 Earnings Call Transcript
Aadi Bioscience, Inc. (AADI) Reports Q4 Loss, Misses Revenue Estimates
Aadi Bioscience, Inc. (AADI) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to loss of $0.52 per share a year ago.
Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update
FYARRO® sales of $6.3 million for Q4 2023 and $24.4 million for FY 2023 representing year-over-year growth of 21% and 60%, respectively Registration-directed PRECISION1 trial of nab-sirolimus in solid tumors with TSC1 or TSC2 inactivating alterations on track to complete...
Source: https://incomestatements.info
Category: Stock Reports